Literature DB >> 8537352

Short isoform of POU factor Brn-3b can form a heterodimer with Brn-3a that is inactive for octamer motif binding.

T Theil1, B Rödel, F Spiegelhalter, T Möröy.   

Abstract

The POU proteins Brn-3a and Brn-3b belong to a family of DNA binding transcription factors that share stretches of extensive homology. Both Brn-3a and Brn-3b are expressed as shorter and longer isoforms. The long form of Brn-3a is able to oncogenically transform primary fibroblasts. By contrast, the short form of Brn-3b (Brn-3b(s)) cannot transform fibroblasts but is able to specifically inhibit the transforming activity of Brn-3a(1). Moreover, Brn-3a(1) can act as a transcriptional transactivator, while Brn-3b(s) is not only unable to do so but in addition specifically inhibits the tranactivating activity of Brn-3a(1). Here, we show that the opposite and antagonistic activities of Brn-3a(1) and Brn-3b(s) proteins are due to their different DNA binding properties; Brn-3a(1) but not Brn-3b(s) can form stable complexes with several octamer-related target DNA sequences. The presence of Brn-3b(s) completely inhibits the binding of Brn-3a(1) to DNA by preventing the formation of Brn-3a(1)-DNA complexes as well as by disrupting preformed complexes. Experiments with GST fusion proteins and in vitro binding studies suggest that the inhibition of Brn-3a(1) activity by Brn-3b(s) occurs via direct interaction of the two transcription factors in solution. Therefore, we hypothesize that Brn-3b(s) can act as a direct antagonist of Brn-3a(1) by inhibiting its DNA binding through the formation of an inactive hetero-oligomeric complex.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8537352     DOI: 10.1074/jbc.270.52.30958

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Hsp-27 induction requires POU4F2/Brn-3b TF in doxorubicin-treated breast cancer cells, whereas phosphorylation alters its cellular localisation following drug treatment.

Authors:  Rieko Fujita; Samir Ounzain; Alice Chun Yin Wang; Richard John Heads; Vishwanie Shanie Budhram-Mahadeo
Journal:  Cell Stress Chaperones       Date:  2011-01-29       Impact factor: 3.667

Review 2.  POU domain transcription factors in embryonic development.

Authors:  G J Veenstra; P C van der Vliet; O H Destrée
Journal:  Mol Biol Rep       Date:  1997-08       Impact factor: 2.316

3.  POU transcription factors Brn-3a and Brn-3b interact with the estrogen receptor and differentially regulate transcriptional activity via an estrogen response element.

Authors:  V Budhram-Mahadeo; M Parker; D S Latchman
Journal:  Mol Cell Biol       Date:  1998-02       Impact factor: 4.272

4.  Autoregulatory sequences are revealed by complex stability screening of the mouse brn-3.0 locus.

Authors:  M Trieu; J M Rhee; N Fedtsova; E E Turner
Journal:  J Neurosci       Date:  1999-08-01       Impact factor: 6.167

5.  Cardiac expression of Brn-3a and Brn-3b POU transcription factors and regulation of Hsp27 gene expression.

Authors:  Saleha R Farooqui-Kabir; James K J Diss; Deborah Henderson; Michael S Marber; David S Latchman; Vishwanie Budhram-Mahadeo; Richard J Heads
Journal:  Cell Stress Chaperones       Date:  2008-03-27       Impact factor: 3.667

6.  The DFNA15 deafness mutation affects POU4F3 protein stability, localization, and transcriptional activity.

Authors:  Sigal Weiss; Irit Gottfried; Itay Mayrose; Suvarna L Khare; Mengqing Xiang; Sally J Dawson; Karen B Avraham
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

7.  A simple technique for the prediction of interacting proteins reveals a direct Brn-3a-androgen receptor interaction.

Authors:  Daniel C Berwick; James K J Diss; Vishwanie S Budhram-Mahadeo; David S Latchman
Journal:  J Biol Chem       Date:  2010-03-12       Impact factor: 5.157

8.  Nubbin isoform antagonism governs Drosophila intestinal immune homeostasis.

Authors:  Bo G Lindberg; Xiongzhuo Tang; Widad Dantoft; Priya Gohel; Shiva Seyedoleslami Esfahani; Jessica M Lindvall; Ylva Engström
Journal:  PLoS Pathog       Date:  2018-03-02       Impact factor: 6.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.